FAQ

DepoCyt

Known as: Depo-Cyt, DepoFoam Encapsulated Cytarabine 
 

Topic mentions per year

Topic mentions per year

1999-2017
012319992017

Related topics

Related topics

3 relations
CytarabineCytarabine liposomeDTC 101

Related mentions per year

Related mentions per year

1962-2018
1960198020002020
DepoCyt
Cytarabine
Cytarabine liposome
DTC 101

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Effects of cholesterol concentration on the interaction of cytarabine with lipid membranes: a molecular dynamics simulation study.
Liposomal cytarabine, DepoCyt, is a chemotherapy agent which is used in cancer treatment. This form of cytarabine has more… (More)
Is this relevant?
2012
2012
Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series
Treatment of leptomeningeal metastasis (LMD) remains challenging due to advanced systemic disease at presentation and limited… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2011
2011
Severe drug shortages impose heavy costs on hospital pharmacies: senate bill might help … or not.
  • Stephen Barlas
  • P & T : a peer-reviewed journal for formulary…
  • 2011
the list of drugs in short supply, perhaps because they are more likely to be subject to discontinuations resulting from… (More)
Is this relevant?
2004
2004
Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
PURPOSE We performed a phase I trial of intrathecal (IT) liposomal cytarabine (DepoCyt; Enzon Pharmaceuticals, Piscataway, NJ and… (More)
Is this relevant?
2003
2003
Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis.
BACKGROUND The authors compared the quality of life of patients with solid tumor neoplastic meningitis treated in a controlled… (More)
Is this relevant?
2002
2002
An Open Label Trial of Sustained-release Cytarabine (DepoCytâ„¢) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis
Drugs currently available for intrathecal administration are cleared rapidly from the CSF. DepoCyt is a slow-release formulation… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2000
Review
2000
Current treatment approaches for neoplastic meningitis: nursing management of patients receiving intrathecal DepoCyt.
PURPOSE/OBJECTIVES To review neoplastic meningitis and the nursing implications for the intrathecal administration of… (More)
Is this relevant?
Review
2000
Review
2000
Clinical pharmacology of encapsulated sustained-release cytarabine.
BACKGROUND The therapeutic effectiveness of chemotherapy is often limited by the inability to sustain cytotoxic concentrations at… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Standard treatment for neoplastic meningitis requires frequent intrathecal (IT) injections of chemotherapy and is only modestly… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.
PURPOSE To evaluate the efficacy and safety of a slow-release formulation of cytarabine (DepoCyt; Chiron Corp, Emeryville, CA… (More)
Is this relevant?